Module

Faculty Responses to Additional Questions on Initiating Antiretroviral Therapy

Source: Answering the Questions: Initiating Antiretroviral Therapy

Faculty Responses to Additional Questions on Initiating Antiretroviral Therapy

Faculty:

John A. Bartlett, MD
Paul E. Sax, MD
Benjamin Young, MD, PhD

CREDIT INFORMATION

Release Date: 06/12/09

Expiration Date: 06/11/10

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Explain risks and benefits of early therapy, that is, initiating antiretroviral therapy in patients with CD4+ cell counts ≥ 350 cells/mm³
Describe strategies for building antiretroviral regimens for patients with baseline drug resistance
Discuss the advantages and disadvantages of novel strategies (ie, other than 2 NRTIs plus a boosted PI or NNRTI) for first-line therapy
Summarize special considerations when caring for pregnant HIV-infected patients and patients older than 50 years of age
Cite evidence that helps guide the appropriate approach to patients with metabolic disorders, particularly hyperlipidemia and renal disease
Recount data about the use of newer agents in first-line therapy

Topics covered include:

Risks and Benefits of Early Therapy
Education for Patients Who Are Distrustful of Conventional Medicine
Planning Therapy for Patients With Transmitted Drug Resistance
Role of Newer Agents in First-line Therapy and Switch Strategies
New Paradigms for First-Line Therapy
Initiating Therapy in Special Populations: Pregnant Patients
Initiating Therapy in Special Populations: Patients Over 50 Years of Age
Initiating Therapy in Special Populations: Substance Abusers Taking Methadone
Initiating Therapy in Special Populations: Hyperlipidemia and Heart Disease
Initiating Therapy in Special Populations: Patients With Hepatitis B
Initiating Therapy in Special Populations: Patients With Cancer

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.